Your browser doesn't support javascript.
loading
MalDA, Accelerating Malaria Drug Discovery.
Yang, Tuo; Ottilie, Sabine; Istvan, Eva S; Godinez-Macias, Karla P; Lukens, Amanda K; Baragaña, Beatriz; Campo, Brice; Walpole, Chris; Niles, Jacquin C; Chibale, Kelly; Dechering, Koen J; Llinás, Manuel; Lee, Marcus C S; Kato, Nobutaka; Wyllie, Susan; McNamara, Case W; Gamo, Francisco Javier; Burrows, Jeremy; Fidock, David A; Goldberg, Daniel E; Gilbert, Ian H; Wirth, Dyann F; Winzeler, Elizabeth A.
Afiliación
  • Yang T; Department of Pediatrics, School of Medicine, University of California, San Diego (UCSD), La Jolla, CA 92093, USA.
  • Ottilie S; Department of Pediatrics, School of Medicine, University of California, San Diego (UCSD), La Jolla, CA 92093, USA.
  • Istvan ES; Department of Internal Medicine, Division of Infectious Diseases, Washington University School of Medicine, Saint Louis, MO 63130, USA; Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, MO 63130, USA.
  • Godinez-Macias KP; Bioinformatics and Systems Biology Graduate Program, University of California, San Diego (UCSD), La Jolla, CA 92093, USA.
  • Lukens AK; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Infectious Disease and Microbiome Program, Broad Institute, Cambridge, MA 02142, USA.
  • Baragaña B; Wellcome Center for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, UK.
  • Campo B; Medicines for Malaria Venture, 1215 Geneva 15, Switzerland.
  • Walpole C; Structural Genomics Consortium, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
  • Niles JC; Department of Biological Engineering, Massachusetts Institute of Technology (MIT), Building 56-341, 77 Massachusetts Avenue, Cambridge MA 02139-4307, USA.
  • Chibale K; Drug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch 7701, South Africa; South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Ronde
  • Dechering KJ; TropIQ Health Sciences, 6534 AT, Nijmegen, The Netherlands.
  • Llinás M; Department of Biochemistry and Molecular Biology and Department of Chemistry, Huck Center for Malaria Research, The Pennsylvania State University, University Park, PA 16082, USA.
  • Lee MCS; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
  • Kato N; Global Health Drug Discovery Institute, Zhongguancun Dongsheng International Science Park, 1 North Yongtaizhuang Road, Beijing 100192, China.
  • Wyllie S; Wellcome Center for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, UK.
  • McNamara CW; Calibr, a division of The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Gamo FJ; Tres Cantos Medicines Development Campus, Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, 28760, Madrid, Spain.
  • Burrows J; Medicines for Malaria Venture, 1215 Geneva 15, Switzerland.
  • Fidock DA; Department of Microbiology and Immunology and Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Goldberg DE; Department of Internal Medicine, Division of Infectious Diseases, Washington University School of Medicine, Saint Louis, MO 63130, USA; Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, MO 63130, USA.
  • Gilbert IH; Wellcome Center for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, UK.
  • Wirth DF; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Infectious Disease and Microbiome Program, Broad Institute, Cambridge, MA 02142, USA.
  • Winzeler EA; Department of Pediatrics, School of Medicine, University of California, San Diego (UCSD), La Jolla, CA 92093, USA. Electronic address: ewinzeler@health.ucsd.edu.
Trends Parasitol ; 37(6): 493-507, 2021 06.
Article en En | MEDLINE | ID: mdl-33648890
ABSTRACT
The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories. The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process by identifying new, essential, druggable targets. In addition, it seeks to produce early lead inhibitors that may be advanced into drug candidates suitable for preclinical development and subsequent clinical testing in humans. By sharing resources, including expertise, knowledge, materials, and reagents, the consortium strives to eliminate the structural barriers often encountered in the drug discovery process. Here we discuss the mission of the consortium and its scientific achievements, including the identification of new chemically and biologically validated targets, as well as future scientific directions.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Descubrimiento de Drogas / Malaria / Antimaláricos Idioma: En Revista: Trends Parasitol Asunto de la revista: PARASITOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Descubrimiento de Drogas / Malaria / Antimaláricos Idioma: En Revista: Trends Parasitol Asunto de la revista: PARASITOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos